Lung transplantation: A treatment option in end-stage lung disease;Lungentransplantation - Therapieoption bei Lungenerkrankungen im Endstadium

Deutsches Arzteblatt International

Volumn 111, Issue 7, 2014, Pages

  Hartert, Marc ^a   Senbaklavaci, Ömer ^a   Gohrbandt, Bernhard ^a   Fischer, Berthold M ^a   Buhl, Roland ^a   Vahl, Christian Friedrich ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BRONCHIECTASIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; END STAGE LUNG DISEASE; FIBROSING ALVEOLITIS; GRAFT FAILURE; GRAFT INFECTION; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG DISEASE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PATIENT SELECTION; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SARCOIDOSIS; SURVIVAL RATE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; FEMALE; GRAFT REJECTION; LUNG DISEASES; MALE; META ANALYSIS; PALLIATIVE THERAPY; PREVALENCE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TERMINAL CARE; TREATMENT OUTCOME;

FEMALE; GRAFT REJECTION; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; PALLIATIVE CARE; PREVALENCE; RISK FACTORS; SURVIVAL RATE; TERMINAL CARE; TREATMENT OUTCOME;

EID: 84903363049     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0107     Document Type: Review

References (156)

1. Kugler C, Gottlieb J, Warnecke G, et al.: Health-related quality of life after solid organ transplantation: A prospective, multiorgan cohort study. Transplantation 2013; 96: 316-23.
2. Singer JP, Singer LG: Quality of life in lung transplantation. Semin Respir Crit Care Med 2013; 34: 421-30.
3. Cooper JD, Pearson FG, Patterson GA, et al.: Technique of successful lung transplantation in humans. J Thorac Cardiovasc Surg 1987; 93: 173-81. (Pubitemid 17020373)
4. Patterson GA, Cooper JD, Goldman B, et al.: Technique of successful clinical double-lung transplantation. Ann Thorac Surg 1988; 45: 626-33.
5. Puri V, Patterson GA: Adult lung transplantation: technical considerations. Semin Thorac Cardiovasc Surg 2008; 20: 152-64.
6. Yusen RD, Christie JD, Edwards LB, et al.: International Society for Heart and Lung Transplantation. The registry of the international society for heart and lung transplantation: thirtieth adult lung and heart-lung transplant report-2013; focus theme: age. J Heart Lung Transplant 2013; 32: 965-78.
7. Deutsche Stiftung Organtransplantation (DSO). Organspende und Transplantation in Deutschland. Jahresbericht 2012. www.dso.de/uploads/tx-dsodl/ DSO-JB12-d-Web.pdf (last accessed on 13 January 2014).
8. Shah PD, Orens JB: Guidelines for the selection of lung-transplant candidates. Curr Opin Organ Transplant 2012; 17: 467-73.
9. Thabut G, Fournier M: Assessing survival benefits from lung transplantation. Rev Mal Respir 2011; 28: 1-6.
10. Machuca TN, Camargo SM, Schio SM, et al.: Lung transplantation for patients older than 65 years: is it a feasible option? Transplant Proc 2011; 43: 233-5.
11. Hook JL, Lederer DJ: Selecting lung transplant candidates: where do current guidelines fall short? Expert Rev Respir Med 2012; 6: 51-61.
12. Kreider M, Hadjiliadis D, Kotloff RM: Candidate selection, timing of listing, and choice of procedure for lung transplantation. Clin Chest Med 2011; 32: 199-211.
13. Beaty CA, George TJ, Kilic A, Conte JV, Shah AS: Pre-transplant malignancy: an analysis of outcomes after thoracic organ transplantation. J Heart Lung Transplant 2013; 32: 202-11.
14. Kanaan R: Indications and contraindications to lung transplant: patient selection. Rev Pneumol Clin 2010; 67: 5-14.
15. Smits JM, Vanhaecke J, Haverich A, et al.: Waiting for a thoracic transplant in Eurotransplant. Transpl Int 2006; 19: 54-66.
16. Orens JB, Estenne M, Arcasoy S, et al.: International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-55. (Pubitemid 43963375)
17. Li M, Mathur S, Chowdhury NA, Helm D, Singer LG: Pulmonary rehabilitation in lung transplant candidates. J Heart Lung Transplant 2013; 32: 626-32.
18. Bartels MN, Armstrong HF, Gerardo RE, et al.: Evaluation of pulmonary function and exercise performance by cardiopulmonary exercise testing before and after lung transplantation. Chest 2011; 140: 1604-11.
19. Strueber M, Reichenspurner H: Die Einführung des Lungenallokations- Scores für die Lungentransplantation in Deutschland. Dtsch Arztebl 2011; 108: A-2424.
20. Yusen RD: Technology and outcomes assessment in lung transplantation. Proc Am Thorac Soc 2009; 6: 128-36.
21. Gottlieb J: Update on lung transplantation. Ther Adv Respir Dis 2008; 2: 237-47.
22. Penninga L, Penninga EI, Møller CH, Iversen M, Steinbrüchel DA, Gluud C: Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev 2013; 31: 5.
23. Floreth T, Bhorade SM: Current trends in immunosuppression for lung transplantation. Semin Respir Crit Care Med 2010; 31: 172-8.
24. de Pablo A, Santos F, Solé A, et al.: Recommendations on the use of everolimus in lung transplantation. Transplant Rev 2013; 27: 9-16.
25. Swarup R, Allenspach LL, Nemeh HW, Stagner LD, Betensley AD: Timing of basiliximab induction and development of acute rejection in lung transplant patients. J Heart Lung Transplant 2011; 30: 1228-35.
26. Todd JL, Palmer SM: Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 2011; 140: 502-8.
27. Uhlin M, Mattsson J, Maeurer M: Update on viral infections in lung transplantation. Curr Opin Pulm Med 2012; 18: 264-70.
28. Carmona EM, Limper AH: Update on the diagnosis and treatment of pneumocystis pneumonia. Ther Adv Respir Dis 2011; 5: 41-59.
29. Schuurmans MM, Benden C, Inci I: Practical approach to early postoperative management of lung transplant recipients. Swiss Med Wkly 2013; 143: w13773.
30. Vivodtzev I, Pison C, Guerrero K, et al.: Benefits of home-based endurance training in lung transplant recipients. Respir Physiol Neurobiol 2011; 177: 189-98.
31. Suzuki Y, Cantu E, Christie JD: Primary graft dysfunction. Semin Respir Crit Care Med 2013; 34: 305-19.
32. Dilling DF, Glanville AR: Advances in lung transplantation: the year in review. Heart Lung Transplant 2011; 30: 247-51.
33. Glanville AR: The role of surveillance bronchoscopy post-lung transplantation. Semin Respir Crit Care Med 2013; 34: 414-20.
34. Sims KD, Blumberg EA: Common infections in the lung transplant recipient. Clin Chest Med 2011; 32: 327-41.
35. Porhownik NR: Airway complications post lung transplantation. Curr Opin Pulm Med 2013; 19: 174-80.
36. Belli EV, Landolfo K, Keller C, Thomas M, Odell J: Lung cancer following lung transplant: Single institution 10 year experience. Lung Cancer 2013; 81: 451-4.
37. Muchtar E, Kramer MR, Vidal L, et al.: Posttransplantation lymphoproliferative disorder in lung transplant recipients: A 15-year single institution experience. Transplantation 2013; 96: 657-63.
38. Robbins HY, Arcasoy SM: Malignancies following lung transplanta - tion. Clin Chest Med 2011; 32: 343-55.
39. Li M, Mathur S, Chowdhury NA, Helm D, Singer LG: Pulmonary rehabilitation in lung transplant candidates. J Heart Lung Transplant 2013; 32: 626-32.
40. Shah RJ, Kotloff RM: Lung transplantation for obstructive lung diseases. Semin Respir Crit Care Med 2013; 34: 288-96.
41. Singer JP, Chen J, Blanc PD, Leard LE, Kukreja J, Chen H: A thematic analysis of quality of life in lung transplant: the existing evidence and implications for future directions. Am J Transplant 2013; 13: 839-50.
42. Boffini M, Ranieri VM, Rinaldi M: Lung transplantation: is it still an experimental procedure? Curr Opin Crit Care 2010; 16: 53-61.
43. Knoop C, Estenne M: Disease-specific approach to lung transplantation. Curr Opin Organ Transplant 2009; 14: 466-70.
44. Date H: Update on living-donor lobar lung transplantation. Curr Opin Organ Transplant 2011; 16: 453-7.
45. Panocchia N, Bossola M, Silvestri P, et al.: Ethical evaluation of risks related to living donor transplantation programs. Transplant Proc 2013; 45: 2601-3.
46. Christie JD, Edwards LB, Kucheryavaya AY, et al.: The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31: 1073-86.
47. Kreider M, Kotloff RM: Selection of candidates for lung transplantation. Proc Am Thorac Soc 2009; 6: 20-7.
48. Todd JL, Palmer SM: Lung transplantation in advanced COPD: is it worth it? Semin Respir Crit Care Med 2010; 31: 365-72.
49. Shah RJ, Kotloff RM: Lung transplantation for obstructive lung diseases. Semin Respir Crit Care Med 2013; 34: 288-96.
50. Eskander A, Waddell TK, Faughnan ME, Chowdhury N, Singer LG: BODE index and quality of life in advanced chronic obstructive pulmonary disease before and after lung transplantation. J Heart Lung Transplant 2011; 30: 1334-41.
51. Gottlieb J: Lung transplantation for interstitial lung diseases and pulmonary hypertension. Semin Respir Crit Care Med 2013; 34: 281-7.
52. Corris PA: Lung transplantation for cystic fibrosis and bronchiectasis. Semin Respir Crit Care Med 2013; 34: 297-304.
53. Rosenblatt RL: Lung transplantation in cystic fibrosis. Respir Care 2009; 54: 777-87.
54. Lordan JL, Corris PA: Pulmonary arterial hypertension and lung transplantation. Expert Rev Respir Med 2011; 5: 441-54.
55. Tomaszek SC, Fibla JJ, Dierkhising RA, et al.: Outcome of lung transplantation in elderly recipients. Eur J Cardiothorac Surg 2011; 39: 726-31.
56. Thabut G, Ravaud P, Christie JD: Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1156-63. (Pubitemid 351717576)
57. Fischer S, Meyer K, Tessmann R, et al.: Outcome following single vs bilateral lung transplantation in recipients 60 years of age and older. Transplant Proc 2005; 37: 1369-70. (Pubitemid 40590890)
58. Dierich M, Fuehner T, Welte T, Simon A, Gottlieb J: Lung transplantation. Indications, long-term results and special impact of follow-up care. Internist 2009; 50: 561-71.
59. Jackson SH, Weale MR, Weale RA: Biological age - what is it and can it be measured? Arch Gerontol Geriatr 2003; 36: 103-15. (Pubitemid 36279153)
60. Reynaud-Gaubert M, Boniface S, Métivier AC, Kessler R: When should patients be referred by the physician to the lung transplant team? Patient selection, indications, timing of referral and preparation for lung transplantation. Rev Mal Respir 2008; 25: 1251-9.
61. Gottlieb J, Welte T, Höper MM, Strüber M, Niedermeyer J: Lung transplantation. Possibilities and limitations. Internist 2004; 45: 1246-59.
62. Florian J, Rubin A, Mattiello R, da Fontoura FF, Camargo de J, Teixeira PJ: Impact of pulmonary rehabilitation on quality of life and functional capacity in patients on waiting lists for lung transplantation. J Bras Pneumol 2013; 39: 349-56.
63. Wickerson L, Mathur S, Helm D, Singer L, Brooks D: Physical activity profile of lung transplant candidates with interstitial lung disease. J Cardiopulm Rehabil Prev 2013; 33: 106-12.
64. Langer D, Cebrià i Iranzo MA, Burtin C, et al.: Determinants of physical activity in daily life in candidates for lung transplantation. Respir Med 2012; 106: 747-54.
65. Mathur S, Hornblower E, Levy RD: Exercise training before and after lung transplantation. Phys Sportsmed 2009; 37: 78-87.
66. de Pablo A, Juarros L, Jodra S, et al.: Lung Transplantation Unit. Analysis of patients referred to a lung transplantation unit. Transplant Proc 2013; 45: 2351-6.
67. Toyoda Y, Bhama JK, Shigemura N, et al.: Efficacy of extracorporeal membrane oxygenation as a bridge to lung transplantation. J Thorac Cardiovasc Surg 2013; 145: 1065-70.
68. Hoopes CW, Kukreja J, Golden J, Davenport DL, Diaz-Guzman E, Zwischenberger JB: Extracorporeal membrane oxygenation as a bridge to pulmonary transplantation. J Thorac Cardiovasc Surg 2013; 145: 862-7.
69. Orens JB, Garrity ER Jr: General overview of lung transplantation and review of organ allocation. Proc Am Thorac Soc 2009; 6: 13-9.
70. Nakamura Y, Tanaka K, Shigematsu R, Nakagaichi M, Inoue M, Homma T: Effects of aerobic training and recreational activities in patients with chronic obstructive pulmonary disease. Int J Rehabil Res 2008; 31: 275-83.
71. Keating D, Levvey B, Kotsimbos T, et al.: Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc 2009; 41: 289-91.
72. Wille KM, Harrington KF, deAndrade JA, Vishin S, Oster RA, Kaslow RA: Disparities in lung transplantation before and after introduction of the lung allocation score. J Heart Lung Transplant 2013; 32: 684-92.
73. McShane PJ, Garrity ER Jr: Impact of the lung allocation score. Semin Respir Crit Care Med 2013; 34: 275-80.
74. Smits JM, Nossent GD, de Vries E, et al.: Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant. J Heart Lung Transplant 2011; 30: 22-8.
75. Sommer W, Kühn C, Tudorache I, et al.: Extended criteria donor lungs and clinical outcome: Results of an alternative allocation algorithm. J Heart Lung Transplant 2013; 32: 1065-72.
76. Pêgo-Fernandes PM, Samano MN, Fiorelli AI, et al.: Recommendations for the use of extended criteria donors in lung transplantation. Transplant Proc 2011; 43: 216-9.
77. Smits JM, van der Bij W, Van Raemdonck D, et al.: Defining an extended criteria donor lung: an empirical approach based on the Eurotransplant experience. Transpl Int 2011; 24: 393-400.
78. Meers C, van Raemdonck D, Verleden GM, et al.: The number of lung transplants can be safely doubled using extended criteria donors; a single-center review. Transpl Int 2010; 23: 628-35.
79. Machuca TN, Schio SM, Camargo SM, et al.: Prognostic factors in lung transplantation: the Santa Casa de Porto Alegre experience. Transplantation 2011; 91: 1297-303.
80. Fitzsullivan E, Gries CJ, Phelan P, et al.: Reduction in airway complications after lung transplantation with novel anastomotic technique. Ann Thorac Surg 2011; 92: 309-15.
81. Murthy SC, Gildea TR, Machuzak MS: Anastomotic airway complications after lung transplantation. Curr Opin Organ Transplant 2010; 15: 582-7.
82. Iga N, Oto T, Okada M, et al.: Detection of airway ischaemic damage after lung transplantation by using autofluorescence imaging bronchoscopy. Eur J Cardiothorac Surg 2013 (epub ahead of print)
83. Samano MN, Minamoto H, Junqueira JJ, et al.: Bronchial complications following lung transplantation. Transplant Proc 2009; 41: 921-6.
84. Weder W, Inci I, Korom S, et al.: Airway complications after lung transplantation: risk factors, prevention and outcome. Eur J Cardiothorac Surg 2009; 35: 293-8.
85. Moreno P, Alvarez A, Algar FJ, et al.: Incidence, management and clinical outcomes of patients with airway complications following lung transplantation. Eur J Cardiothorac Surg 2008; 34: 1198-205.
86. Pettersson GB, Karam K, Thuita L, et al.: Comparative study of bronchial artery revascularization in lung transplantation. J Thorac Cardiovasc Surg 2013; 146: 894-900.
87. Pettersson GB, Yun JJ, Nørgaard MA: Bronchial artery revascularization in lung transplantation: techniques, experience, and out - comes. Curr Opin Organ Transplant 2010; 15: 572-7.
88. Witt CA, Hachem RR: Immunosuppression: what's standard and what's new? Semin Respir Crit Care Med 2013; 34: 405-13.
89. Treede H, Glanville AR, Klepetko W, et al.: European and Australian investigators in lung transplantation. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant 2012; 31: 797-804.
90. Benden C, Danziger-Isakov L, Faro A: New developments in treatment after lung transplantation. Curr Pharm Des 2012; 18: 737-46.
91. Bosma OH, Vermeulen KM, Verschuuren EA, Erasmus ME, van der Bij W: Adherence to immunosuppression in adult lung transplant recipients: prevalence and risk factors. J Heart Lung Transplant 2011; 30: 1275-80.
92. Peddi VR, Wiseman A, Chavin K, Slakey D: Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev 2013; 27: 97-107.
93. von Suesskind-Schwendi M, Brunner E, Hirt SW, et al.: Suppres - sion of bronchiolitis obliterans in allogeneic rat lung transplanta - tion-effectiveness of everolimus. Exp Toxicol Pathol 2013; 65: 383-9.
94. Säemann MD, Haidinger M, Hecking M, Hörl WH, Weichhart T: The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009; 9: 2655-61.
95. Verleden SE, Vandermeulen E, Ruttens D, et al.: Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS). Semin Respir Crit Care Med 2013; 34: 352-60.
96. Wiita AP, Roubinian N, Khan Y, et al.: Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis 2012; 14: 248-58.
97. Patel N, Snyder LD, Finlen-Copeland A, Palmer SM: Is prevention the best treatment? CMV after lung transplantation. Am J Transplant 2012; 12: 539-44.
98. Zamora MR, Budev M, Rolfe M, et al.: RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183: 531-8.
99. Lease ED, Zaas DW: Update on infectious complications following lung transplantation. Curr Opin Pulm Med 2011; 17: 206-9.
100. Bridevaux PO, Aubert JD, Soccal PM, et al.: Incidence and out - comes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax 2014; 69: 32-8.
101. Diez Martinez P, Pakkal M, Prenovault J, et al.: Postoperative imaging after lung transplantation. Clin Imaging 2013; 37: 617-23.
102. Patel JK, Kobashigawa JA: Thoracic organ transplantation: laboratory methods. Methods Mol Biol 2013; 1034: 127-43.
103. Nakajima T, Palchevsky V, Perkins DL, Belperio JA, Finn PW: Lung transplantation: infection, inflammation, and the microbiome. Semin Immunopathol 2011; 33: 135-56.
104. Verleden GM, Vos R, Verleden SE, et al.: Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 2011; 92: 703-8.
105. Lease ED, Zaas DW: Complex bacterial infections pre- and posttransplant. Semin Respir Crit Care Med 2010; 31: 234-42.
106. Sengpiel J, Fuehner T, Kugler C, et al.: Use of telehealth technology for home spirometry after lung transplantation: a randomized controlled trial. Prog Transplant 2010; 20: 310-7.
107. Verleden GM, Vos R, De Vleeschauwer SI, et al.: Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl Int 2009; 22: 771-9.
108. Dauriat G, Mal H, Thabut G, et al.: Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006; 81: 746-50.
109. Benden C, Rea F, Behr J, et al.: Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant 2009; 28: 1-7.
110. Hayes D Jr, Galantowicz M, Yates AR, Preston TJ, Mansour HM, McConnell PI: Venovenous ECMO as a bridge to lung transplant and a protective strategy for subsequent primary graft dysfunc - tion. J Artif Organs 2013; 16: 382-5.
111. Shah RJ, Diamond JM, Cantu E, et al.: Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation. Chest 2013; 144: 616-22.
112. Diamond JM, Lee JC, Kawut SM, et al.: Lung Transplant Out - comes Group. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187: 527-34.
113. Dawson KL, Parulekar A, Seethamraju H: Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J Heart Lung Transplant 2012; 31: 1325-6.
114. Martinu T, Howell DN, Palmer SM: Acute cellular rejection and humoral sensitization in lung transplant recipients. Semin Respir Crit Care Med 2010; 31: 179-88.
115. Weigt SS, DerHovanessian A, Wallace WD, Lynch JP 3rd, Belperio JA: Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation. Semin Respir Crit Care Med 2013; 34: 336-51.
116. Atanasova S, Hirschburger M, Jonigk D, et al.: A relevant experimental model for human bronchiolitis obliterans syndrome. J Heart Lung Transplant 2013 ; 32: 1131-9.
117. Suzuki H, Lasbury ME, Fan L, et al.: Role of complement activation in obliterative bronchiolitis post-lung transplantation. J Immunol 2013; 191: 4431-9.
118. Sato M, Ohmori-Matsuda K, Saito T, et al.: Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2013; 32: 484-91.
119. McManigle W, Pavlisko EN, Martinu T: Acute cellular and antibody-mediated allograft rejection. Semin Respir Crit Care Med 2013; 34: 320-35.
120. Mihalek AD, Rosas IO, Padera RF Jr, et al.: Interstitial pneumonitis and the risk of chronic allograft rejection in lung transplant recipients. Chest 2013; 143: 1430-5.
121. Verleden SE, Ruttens D, Vandermeulen E, et al.: Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ? Transplantation 2013; 95: 1167-72.
122. Martinu T, Chen DF, Palmer SM: Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc 2009; 6: 54-65.
123. Mason DP, Rajeswaran J, Li L, et al.: Effect of changes in postoperative spirometry on survival after lung transplantation. J Thorac Cardiovasc Surg 2012; 144: 197-203.
124. Husain S, Resende MR, Rajwans N, et al.: Elevated CXCL10 (IP-10) in bronchoalveolar lavage fluid is associated with acute cellular rejection after human lung transplantation. Transplanta - tion 2013; 97: 90-7.
125. Krustrup D, Madsen CB, Iversen M, Engelholm L, Ryder LP, Andersen CB: The number of regulatory T cells in transbronchial lung allograft biopsies is related to FoxP3 mRNA levels in bronchoalveolar lavage fluid and to the degree of acute cellular rejection. Transpl Immunol 2013; 29: 71-5.
126. Schlischewsky E, Fuehner T, Warnecke G, et al.: Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. Transpl Infect Dis 2013; 15: 60-9.
127. Sandrini A, Glanville AR: The controversial role of surveillance bronchoscopy after lung transplantation. Curr Opin Organ Transplant 2009; 14: 494-8.
128. Thompson ML, Flynn JD, Clifford TM: Pharmacotherapy of lung transplantation: an overview. J Pharm Pract 2013; 26: 5-13.
129. Sweet SC: Induction therapy in lung transplantation. Transpl Int 2013; 26: 696-703.
130. Paraskeva M, McLean C, Ellis S, et al.: Acute fibrinoid organizing pneumonia after lung transplantation. Am J Respir Crit Care Med 2013; 187: 1360-8.
131. Shields RK, Clancy CJ, Minces LR, et al.: Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes. J Heart Lung Transplant 2012; 31: 1199-206.
132. Verleden GM, Vos R, van Raemdonck D, Vanaudenaerde B: Pulmonary infection defense after lung transplantation: does airway ischemia play a role? Curr Opin Organ Transplant 2010; 15: 568-71.
133. Prado e Silva M, Soto SF, Almeida FM, et al.: Immunosuppression effects on airway mucociliary clearance: comparison between two triple therapies. Ann Thorac Surg 2013; 96: 473-7.
134. Aaron SD, Vandemheen KL, Ramotar K, et al.: Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 2010; 304: 2145-53.
135. De Soyza A, Meachery G, Hester KL, et al.: Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant 2010; 29: 1395-404.
136. Hafkin J, Blumberg E: Infections in lung transplantation: new insights. Curr Opin Organ Transplant 2009; 14: 483-7.
137. Nicolls MR, Zamora MR: Bronchial blood supply after lung transplantation without bronchial artery revascularization. Curr Opin Organ Transplant 2010; 15: 563-7.
138. Lund LH, Edwards LB, Kucheryavaya AY, et al.: International Society for Heart and Lung Transplantation. The registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report-2013; focus theme: age. J Heart Lung Transplant 2013; 32: 951-64.
139. Ahmad S, Shlobin OA, Nathan SD: Pulmonary complications of lung transplantation. Chest 2011; 139: 402-11.
140. Shofer SL, Wahidi MM, Davis WA, et al.: Significance of and risk factors for the development of central airway stenosis after lung transplantation. Am J Transplant 2013; 13: 383-9.
141. Castleberry AW, Worni M, Kuchibhatla M, et al.: A comparative analysis of bronchial stricture after lung transplantation in recipients with and without early acute rejection. Ann Thorac Surg 2013; 96: 1008-18.
142. Barnard JB, Davies O, Curry P, et al.: Size matching in lung transplantation: An evidence-based review. J Heart Lung Transplant 2013; 32: 849-60.
143. Eberlein M, Reed RM, Bolukbas S, et al.: Lung size mismatch and survival after single and bilateral lung transplantation. Ann Thorac Surg 2013; 96: 457-63.
144. Santacruz JF, Mehta AC: Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis. Proc Am Thorac Soc 2009; 6: 79-93.
145. Fuehner T, Suhling H, Greer M, et al.: Biodegradable stents after lung transplantation. Transpl Int 2013; 26: e58-60.
146. Paradela de la Morena M, De La Torre Bravos M, Prado RF, et al.: Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment. Transplant Proc 2010; 42: 3217-9.
147. See VY, Roberts-Thomson KC, Stevenson WG, Camp PC, Koplan BA: Atrial arrhythmias after lung transplantation: epidemiology, mechanisms at electrophysiology study, and outcomes. Circ Arrhythm Electrophysiol 2009; 2: 504-10.
148. Hall EC, Pfeiffer RM, Segev DL, Engels EA: Cumulative incidence of cancer after solid organ transplantation. Cancer 2013; 119: 2300-8.
149. Neuringer IP: Posttransplant lymphoproliferative disease after lung transplantation. Clin Dev Immunol 2013; 2013: 430209.
150. Bhaskaran A, Hosseini-Moghaddam SM, Rotstein C, Husain S: Mold infections in lung transplant recipients. Semin Respir Crit Care Med 2013; 34: 371-9.
151. Singer J, Yelin EH, Katz PP, et al.: Respiratory and skeletal muscle strength in chronic obstructive pulmonary disease: impact on exercise capacity and lower extremity function. J Cardiopulm Rehabil Prev 2011; 31: 111-9.
152. Wickerson L, Mathur S, Brooks D: Exercise training after lung transplantation: a systematic review. J Heart Lung Transplant 2010; 29: 497-503.
153. Ihle F, Neurohr C, Huppmann P, et al.: Munich Lung Transplant Group. Effect of inpatient rehabilitation on quality of life and exercise capacity in long-term lung transplant survivors: A prospective, randomized study. J Heart Lung Transplant 2011; 30: 912-9.
154. Suissa S, Dell'Aniello S, Ernst P: Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957-63.
155. Shigemura N, Sclabassi RJ, Bhama JK, et al.: Early major neurologic complications after lung transplantation: incidence, risk factors, and outcome. Transplantation 2013; 95: 866-71.
156. Yusen RD: Survival and quality of life of patients undergoing lung transplant. Clin Chest Med 2011; 32: 253-64.